Literature DB >> 32420265

Safety and effectiveness of reoperation for persistent or recurrent drug refractory secondary hyperparathyroidism.

Lei Zhu1, Feng Cheng1, Xi Zhu1, Bin Zhou1, Yonghong Xu1, Yong Wu1, Chuxiao Shao1.   

Abstract

BACKGROUND: Drug-refractory secondary hyperparathyroidism (SHPT) is the most common complication in patients with chronic renal failure (CRF). Although surgery is the most effective and safe method for drug-refractory SHPT, the condition may persist or recur after the primary surgery, and reoperation is often required in these patients. The purpose of our current study was to evaluate the safety and effectiveness of reoperation for drug-refractory SHPT.
METHODS: The clinical data of 15 patients requiring reoperation after a surgery for drug-refractory SHPT in our hospital from 2010 to 2019 were retrospectively analyzed. Changes in biochemical markers including intact parathyroid hormone (iPTH), blood calcium (Ca), blood phosphorus (P), alkaline phosphatase (ALP), and blood calcium phosphorus product (Ca*P) were compared before and after the surgery, and the effectiveness and complications of the reoperation were summarized.
RESULTS: The reoperation was successful in all the 15 patients after a single attempt. Routine pathological examinations identified a total of 25 parathyroid glands, of which 10 were in the neck in situ, 5 were ectopic in the neck, and 10 were in the forearm. The ectopic parathyroid glands were located inside the thyroid gland (n=1), anterior superior mediastinum (n=1), or thymus (n=3). Surgical treatment significantly improved clinical symptoms such as skin pruritus and bone pain. Blood iPTH, Ca, P, ALP, and Ca*P were significantly reduced (P<0.05 or P<0.01) after surgery. Hypothyroidism occurred in 1 patient; 4 patients undergoing orthotopic neck surgery developed transient hoarseness, which were alleviated within 6 months; no severe complications such as bleeding or death were noted. No recurrence occurred during the 6-month follow-up.
CONCLUSIONS: Reoperation is safe and effective for drug-refractory SHPT. Preoperative imaging should be performed to achieve accurate positioning, and the recurrent laryngeal nerve should be closely monitored during surgery. The purpose of the reoperation is to remove all possible parathyroid tissues to avoid recurrence. 2020 Gland Surgery. All rights reserved.

Entities:  

Keywords:  Drug-refractory; parathyroidectomy; reoperation; secondary hyperparathyroidism (SHPT)

Year:  2020        PMID: 32420265      PMCID: PMC7225451          DOI: 10.21037/gs-20-391

Source DB:  PubMed          Journal:  Gland Surg        ISSN: 2227-684X


  11 in total

Review 1.  [Arteriosklerosis and "osteoporosis" in patients with chronic kidney disease: same same, but different!]

Authors:  Dusan Harmacek; Spiros Arampatzis
Journal:  Ther Umsch       Date:  2018

Review 2.  [Ectopic tissue of the thyroid gland and the parathyroid glands].

Authors:  S Theurer; U Siebolts; K Lorenz; H Dralle; K W Schmid
Journal:  Pathologe       Date:  2018-09       Impact factor: 1.011

Review 3.  Intermittent neural monitoring of the recurrent laryngeal nerve in surgery for recurrent goiter.

Authors:  Beata Wojtczak; Marcin Barczyński
Journal:  Gland Surg       Date:  2016-10

4.  Kidney Disease Improving Global Outcomes guidelines and parathyroidectomy for renal hyperparathyroidism.

Authors:  Sarah C Oltmann; Tariq M Madkhali; Rebecca S Sippel; Herbert Chen; David F Schneider
Journal:  J Surg Res       Date:  2015-04-18       Impact factor: 2.192

5.  Recent changes in therapeutic approaches and association with outcomes among patients with secondary hyperparathyroidism on chronic hemodialysis: the DOPPS study.

Authors:  Francesca Tentori; Mia Wang; Brian A Bieber; Angelo Karaboyas; Yun Li; Stefan H Jacobson; Vittorio E Andreucci; Masafumi Fukagawa; Luc Frimat; David C Mendelssohn; Friedrich K Port; Ronald L Pisoni; Bruce M Robinson
Journal:  Clin J Am Soc Nephrol       Date:  2014-12-16       Impact factor: 8.237

Review 6.  Secondary and tertiary hyperparathyroidism.

Authors:  Sophie A Jamal; Paul D Miller
Journal:  J Clin Densitom       Date:  2012-12-23       Impact factor: 2.617

Review 7.  Network meta-analysis of surgical treatment for secondary hyperparathyroidism.

Authors:  Jianzhong Hou; Haojie Shan; Yingchao Zhang; Xianzhao Deng; Bomin Guo; Jie Kang; Bo Wu; Youben Fan
Journal:  Am J Otolaryngol       Date:  2019-12-21       Impact factor: 1.808

8.  Efficacy and safety of cinacalcet and active vitamin D in the treatment of secondary hyperparathyroidism in patients with chronic kidney disease: a network meta-analysis.

Authors:  Li-Hua Ni; Cheng Yuan; Kai-Yun Song; Xiao-Chen Wang; Si-Jie Chen; Li-Ting Wang; Yu-Xia Zhang; Hong Liu; Bi-Cheng Liu; Ri-Ning Tang
Journal:  Ann Transl Med       Date:  2019-07

9.  Reoperation for persistent or recurrent secondary hyperparathyroidism.

Authors:  Alida Abruzzo; Maria Concetta Gioviale; Giuseppe Damiano; Vincenzo Davide Palumbo; Salvatore Buscemi; Giulia Lo Monte; Leonardo Gulotta; Giuseppe Buscemi; Attilio Ignazio Lo Monte
Journal:  Acta Biomed       Date:  2017-10-23

10.  Atypical presentations of parathyroid gland pathology: A pictorial review.

Authors:  Xin-Ying Kowa; Polly Richards; Mona Waterhouse; Laila Parvanta; Ashok Adams
Journal:  Eur J Radiol Open       Date:  2019-11-08
View more
  2 in total

1.  Predictors of hyperkalemia after total parathyroidectomy in patients with drug-refractory secondary hyperparathyroidism.

Authors:  Xi Zhu; Zhouting Li; Xiaofang Xia; Xiaomin Zeng; Feng Cheng; Bin Zhou; Yong Wu; Lei Zhu
Journal:  Gland Surg       Date:  2022-04

2.  Application of nanocarbon negative imaging technology in surgery for secondary hyperparathyroidism.

Authors:  Yu Wu; Ying Liu; Tao Huang; Yasu Jiang; Hua Wang; Zhixian He
Journal:  Gland Surg       Date:  2021-08
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.